Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Long-Term Voclosporin Treatment Looks Promising for Lupus Nephritis Patients

  |  

AURORA 2, a double-blind, phase 3 study, evaluated the long-term safety, tolerability and efficacy of voclosporin compared to placebo in patients with lupus nephritis receiving an additional two years of treatment following completion of the one-year AURORA 1 study. Patients enrolled in AURORA 2 continued to receive the same treatment randomly assigned in AURORA 1, in combination with mycophenolate mofetil and low-dose glucocorticoids. Saxena et al. propose that the rapid renal response achieved with voclosporin treatment has long-term benefits, supported by stable kidney function over the three-year treatment period.

The ACR Urges House to Reverse NIH Research Funding Cuts

  |  

A bill approved last year by the House Appropriations Committee contains dire cuts to funding for the National Institutes of Health. The ACR is urging the House to revise this language and the Senate not to allow these cuts to go through. Contact your legislators to convey the importance of robust investment in the nation’s medical research enterprise and how funding cuts harm patient care.